FIELD: biotechnology.
SUBSTANCE: antibodies to TGFβ3 are presented and pharmaceutical compositions containing same.
EFFECT: invention can find further application in the therapy of fibrosis and other TGFβ-related disorders.
27 cl, 65 dwg, 30 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| MODIFIED IGG ANTIBODIES WHICH BIND TO A TRANSFORMING GROWTH FACTOR BETA-1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2728858C2 |
| ANTIBODIES TARGETING BONE | 2018 |
|
RU2801206C2 |
| SCFV-FC DIMERS WHICH BIND TO THE TRANSFORMING GROWTH FACTOR β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2733286C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| ANTI-FXI/FXIA ANTIBODY, ANTIGEN-BINDING FRAGMENT AND PHARMACEUTICAL APPLICATION THEREOF | 2021 |
|
RU2838408C1 |
